Switch theme
Sign up to access all valuation multiples
Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company’s operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
1946
2.1K+
LTM Revenue $607M
LTM EBITDA $65.6M
$935M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kissei Pharmaceutical has a last 12-month revenue (LTM) of $607M and a last 12-month EBITDA of $65.6M.
In the most recent fiscal year, Kissei Pharmaceutical achieved revenue of $519M and an EBITDA of $128M.
Kissei Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kissei Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $607M | XXX | $519M | XXX | XXX | XXX |
| Gross Profit | $303M | XXX | $256M | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | 49% | XXX | XXX | XXX |
| EBITDA | $65.6M | XXX | $128M | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $39.5M | XXX | $27.6M | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $80.6M | XXX | $76.6M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kissei Pharmaceutical's stock price is JPY 4290 (or $29).
Kissei Pharmaceutical has current market cap of JPY 184B (or $1.3B), and EV of JPY 136B (or $935M).
See Kissei Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $935M | $1.3B | XXX | XXX | XXX | XXX | $1.86 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kissei Pharmaceutical has market cap of $1.3B and EV of $935M.
Kissei Pharmaceutical's trades at 1.9x EV/Revenue multiple, and 7.4x EV/EBITDA.
Equity research analysts estimate Kissei Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kissei Pharmaceutical has a P/E ratio of 15.6x.
See valuation multiples for Kissei Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $935M | XXX | $935M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 14.3x | XXX | 7.4x | XXX | XXX | XXX |
| EV/EBIT | 23.7x | XXX | 49.9x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.6x | XXX | 16.7x | XXX | XXX | XXX |
| EV/FCF | 15.6x | XXX | -27.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKissei Pharmaceutical's last 12 month revenue growth is 2%
Kissei Pharmaceutical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Kissei Pharmaceutical's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kissei Pharmaceutical's rule of X is 15% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kissei Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | -20% | XXX | XXX | XXX |
| Rule of 40 | 27% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 15% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kissei Pharmaceutical acquired XXX companies to date.
Last acquisition by Kissei Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Kissei Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kissei Pharmaceutical founded? | Kissei Pharmaceutical was founded in 1946. |
| Where is Kissei Pharmaceutical headquartered? | Kissei Pharmaceutical is headquartered in Japan. |
| How many employees does Kissei Pharmaceutical have? | As of today, Kissei Pharmaceutical has 2.1K+ employees. |
| Who is the CEO of Kissei Pharmaceutical? | Kissei Pharmaceutical's CEO is Mr. Mutsuo Kanzawa. |
| Is Kissei Pharmaceutical publicy listed? | Yes, Kissei Pharmaceutical is a public company listed on TKS. |
| What is the stock symbol of Kissei Pharmaceutical? | Kissei Pharmaceutical trades under 4547 ticker. |
| When did Kissei Pharmaceutical go public? | Kissei Pharmaceutical went public in 1988. |
| Who are competitors of Kissei Pharmaceutical? | Similar companies to Kissei Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kissei Pharmaceutical? | Kissei Pharmaceutical's current market cap is $1.3B |
| What is the current revenue of Kissei Pharmaceutical? | Kissei Pharmaceutical's last 12 months revenue is $607M. |
| What is the current revenue growth of Kissei Pharmaceutical? | Kissei Pharmaceutical revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Kissei Pharmaceutical? | Current revenue multiple of Kissei Pharmaceutical is 1.5x. |
| Is Kissei Pharmaceutical profitable? | Yes, Kissei Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kissei Pharmaceutical? | Kissei Pharmaceutical's last 12 months EBITDA is $65.6M. |
| What is Kissei Pharmaceutical's EBITDA margin? | Kissei Pharmaceutical's last 12 months EBITDA margin is 11%. |
| What is the current EV/EBITDA multiple of Kissei Pharmaceutical? | Current EBITDA multiple of Kissei Pharmaceutical is 14.3x. |
| What is the current FCF of Kissei Pharmaceutical? | Kissei Pharmaceutical's last 12 months FCF is $59.9M. |
| What is Kissei Pharmaceutical's FCF margin? | Kissei Pharmaceutical's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Kissei Pharmaceutical? | Current FCF multiple of Kissei Pharmaceutical is 15.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
